{"pmid":32503855,"title":"Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.","text":["Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.","Ann Rheum Dis","Monti, Sara","Montecucco, Carlomaurizio","32503855"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Montecucco, Carlomaurizio"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503855","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217957","keywords":["antirheumatic agents","cytokines","familial mediterranean fever"],"locations":["Kobak"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1668892488174141440,"score":9.490897,"similar":[{"pmid":32503853,"title":"COVID-19 infection in a patient with FMF: does colchicine have a protective effect?","text":["COVID-19 infection in a patient with FMF: does colchicine have a protective effect?","Ann Rheum Dis","Kobak, Senol","32503853"],"journal":"Ann Rheum Dis","authors":["Kobak, Senol"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503853","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/annrheumdis-2020-217882","keywords":["antirheumatic agents","familial mediterranean fever","patient care team"],"e_drugs":["Colchicine"],"topics":["Case Report"],"weight":1,"_version_":1668892488224473090,"score":156.3013},{"pmid":32500409,"pmcid":"PMC7270517","title":"Implications of COVID-19 in pediatric rheumatology.","text":["Implications of COVID-19 in pediatric rheumatology.","COVID-19 (coronavirus disease 2019) pandemic caused by SARS-CoV-2, is a global public health issue threatening millions of lives worldwide. Although the infection is mild in most of the affected individuals, it may cause severe clinical manifestations such as acute respiratory distress syndrome or cytokine storm leading to death. Children are affected less, and most experience a milder disease. As rheumatologists, we deal with the uncontrolled response of the immune system, and most of the drugs we use are either immune modulators or immunosuppressants. Thus, the rheumatologists participate in the multidisciplinary management of COVID-19 patients. On the other hand, our patients with rheumatic diseases constitute a vulnerable group in this pandemic. In this review, a systematic literature search was conducted utilizing MEDLINE/PubMed and Scopus databases, and 231 COVID-19 patients with rheumatic diseases have been identified. Only one of these patients was a child. Among these, 9 (3.9%) died due to COVID-19. In light of the current data, the aspects of COVID-19 resembling rheumatic diseases, the possible reasons for why children are affected less severely, the hypothetic role of available vaccines in preventing COVID-19, the unique position of patients with rheumatic diseases in this pandemic, and the use of anti-rheumatic drugs in COVID-19 treatment are discussed.","Rheumatol Int","Batu, Ezgi Deniz","Ozen, Seza","32500409"],"abstract":["COVID-19 (coronavirus disease 2019) pandemic caused by SARS-CoV-2, is a global public health issue threatening millions of lives worldwide. Although the infection is mild in most of the affected individuals, it may cause severe clinical manifestations such as acute respiratory distress syndrome or cytokine storm leading to death. Children are affected less, and most experience a milder disease. As rheumatologists, we deal with the uncontrolled response of the immune system, and most of the drugs we use are either immune modulators or immunosuppressants. Thus, the rheumatologists participate in the multidisciplinary management of COVID-19 patients. On the other hand, our patients with rheumatic diseases constitute a vulnerable group in this pandemic. In this review, a systematic literature search was conducted utilizing MEDLINE/PubMed and Scopus databases, and 231 COVID-19 patients with rheumatic diseases have been identified. Only one of these patients was a child. Among these, 9 (3.9%) died due to COVID-19. In light of the current data, the aspects of COVID-19 resembling rheumatic diseases, the possible reasons for why children are affected less severely, the hypothetic role of available vaccines in preventing COVID-19, the unique position of patients with rheumatic diseases in this pandemic, and the use of anti-rheumatic drugs in COVID-19 treatment are discussed."],"journal":"Rheumatol Int","authors":["Batu, Ezgi Deniz","Ozen, Seza"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500409","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s00296-020-04612-6","keywords":["covid-19","covid-19 virus","familial mediterranean fever","rheumatic disease","sars-cov-2","systemic lupus erythematosus"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668890966294003712,"score":71.54542},{"pmid":32295789,"title":"Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.","text":["Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.","Ann Rheum Dis","Lu, Chenyang","Li, Shasha","Liu, Yi","32295789"],"journal":"Ann Rheum Dis","authors":["Lu, Chenyang","Li, Shasha","Liu, Yi"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295789","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217460","keywords":["antirheumatic agents","cytokines","inflammation"],"topics":["Treatment"],"weight":1,"_version_":1666138493275865088,"score":60.62925},{"pmid":32434823,"title":"Rheumatic diseases in intensive care unit patients with COVID-19.","text":["Rheumatic diseases in intensive care unit patients with COVID-19.","Ann Rheum Dis","Moiseev, Sergey","Avdeev, Sergey","Brovko, Michail","Yavorovskiy, Andrey","Novikov, Pavel I","Umbetova, Karina","Akulkina, Larisa","Tsareva, Natal'ya","Fomin, Victor","32434823"],"journal":"Ann Rheum Dis","authors":["Moiseev, Sergey","Avdeev, Sergey","Brovko, Michail","Yavorovskiy, Andrey","Novikov, Pavel I","Umbetova, Karina","Akulkina, Larisa","Tsareva, Natal'ya","Fomin, Victor"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434823","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/annrheumdis-2020-217676","keywords":["antirheumatic agents","autoimmune diseases","cytokines"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667521393624875009,"score":58.641487},{"pmid":32376597,"title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.","text":["Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.","Ann Rheum Dis","Aouba, Achille","Baldolli, Aurelie","Geffray, Loik","Verdon, Renaud","Bergot, Emmanuel","Martin-Silva, Nicolas","Justet, Aurelien","32376597"],"journal":"Ann Rheum Dis","authors":["Aouba, Achille","Baldolli, Aurelie","Geffray, Loik","Verdon, Renaud","Bergot, Emmanuel","Martin-Silva, Nicolas","Justet, Aurelien"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376597","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1136/annrheumdis-2020-217706","keywords":["antirheumatic agents","biological therapy","cytokines","interleukin 1 receptor antagonist protein","therapeutics"],"topics":["Case Report"],"weight":1,"_version_":1666597097452863489,"score":50.80139}]}